Pentoxifylline prevents concanavalin A-induced hepatitis by reducing tumor necrosis factor α levels and inhibiting adhesion of T lymphocytes to extracellular matrix

Journal of Hepatology

Volumn 29, Issue 1, 1998, Pages 60-67

  Shirin, Haim ^a   Bruck, Rafael ^a   Aeed, Hussein ^a   Frenkel, Daniela ^a   Kenet, Gabriel ^a   Zaidel, Liliana ^a   Avni, Yona ^a   Halpern, Zamir ^a   Hershkoviz, Rami ^b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cytokines; Hepatitis; Pentoxifylline

Indexed keywords

CONCANAVALIN A; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEPATITIS; HISTOPATHOLOGY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0032125209     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80179-7     Document Type: Article

References (47)

1. Strieter RM, Remick DG, Ward PA, Splenger RN, Lynch JP, Larrick J, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 155:1988;1230-1236.
2. Neuner P, Klosner G, Schauer E, Pourmojib N, Macheiner W, Grunwald C, et al. Pentoxifylline in vivo down-regulates the release of IL-1/β, IL-6, IL-8 and tumor necrosis factor by human peripheral blood mononuclear cells. Immunology. 83:1994;262-267.
3. Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, Huynh A, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective randomized trial. Blood. 82:1993;732-736.
4. Dezube BJ, Pardee AB, Chapman B, Beckett CA, Korvick JA, Novick WJ, et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J Acquir Immune Defic Syndr. 6:1993;787-794.
5. Neuner P, Klosner G, Ponrmojib M, Knobler R, Schwarz T. Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology. 90:1997;435-439.
6. Wang P, Ba FZ, Morrison M.H, Ayala A, Chaudry IH. Mechanism of the beneficial effects of pentoxifylline on hepatocellular function after trauma hemorrhage and resuscitation. Surgery. 112:1992;451-458.
7. Jilg S, Baxsig J, Leist M, Kusters S, Volk HD, Wendel A. Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methylxanthine action in murine models of endotoxic shock. J Pharmacol Exp Ther. 278:1996;421-431.
8. Soupison T, Yang S, Bernard C, Moreau R, Kirstetter P, D'Almeida M, et al. Acute hemodynamic responses and inhibition of tumor necrosis factor-alpha by pentoxifylline in rats with cirrhosis. Clin Sci. 91:1996;29-33.
9. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest. 90:1992;196-203.
10. Gantner F, Leist M, Loshe AW, Germann PG, Tiegs G. Concanavalin A -induced T cell mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology. 21:1995;190-198.
11. Lis H, Sharon N. Biological properties of lectins. Liener IE, Sharon N, Goldstein IJ. The Lectins: Properties, Function and Applications in Biology and Medicine. 1986;265-291 Academic Press, New York.
12. Tiegs G. Immunotoxicology of host-response-mediated experimental liver injury. J Hepatol. 21:1994;890-903.
13. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factor and protection by interleukin 6. J Exp Med. 179:1994;1529-1537.
14. Mizuhara H, Uno M, Seki N, Yamashita M, Yamaoka M, Ogawa T, et al. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology. 23:1996;1608-1615.
15. Bruck R, Shirin H, Hershkoviz R, Lider O, Kenet G, Aeed H, et al. Analysis of Arg-Gly Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A-induced hepatitis in mice. Gut. 40:1997;133-138.
16. Leist M, Auer-Barth S, Wendel A. Tumor necrosis factor production in the perfused mouse liver and its pharmacological modulation by methylxanthines. J Pharmacol Exp Ther. 276:1996;968-976.
17. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 110:1991;192-198.
18. Pain JA, Bailey ME. Experimental and clinical study of lactulose in obstructive jaundice. Br J Surg. 73:1986;775-778.
19. Bemelmans MHA, Gouma DJ, Greve JW, Buurman WA. Effect of antitumour necrosis factor treatment on circulating tumour necrosis factor levels and mortality after surgery in jaundiced mice. Br J Surg. 80:1993;1055-1058.
20. Greve JW, Gouma DJ, Leeuwen PAM, Buurman WA. Lactulose inhibits endotoxin tumour necrosis factor production by monocytes. An in vitro study. Gut. 31:1990;198-203.
21. Shimizu Y, van Saventer GA, Horgan KJ, Shaw KJ. Regulated expression and binding of three VLA (β1) integrin receptors on T cells. Nature. 345:1990;250-253.
22. Greenspoon N, Hershkoviz R, Alon R, Varon D, Shemkman B, Marx G, et al. Structural analysis of integrin recognition and the inhibition of integrin-mediated cell functions by novel nonpeptidic surrogates of the Arg-Gly-Asp cell adhesion motif. Biochemistry. 32:1993;1001-1008.
23. + T lymphocyte binding to fibronectin and immune cell accumulation in inflammatory sites by novel nonpeptidic mimetics of the Arg-Gly-Asp cell adhesion motif. Clin Exp Immunol. 95:1994;270-276.
24. Magliulo E, Deitz A, Torre D, Portelli V, Scevola D. Endotoxin spillover in viral hepatitis. Infection. 7:1979;155-156.
25. Scevola D, Magliulo E, Trpin L, Benzi-Cipelli R, Bernardi R. Control of endotoxemia in liver disease by lactulose and paromomycin. Boll 1st Sieroter Milan. 58:1979;242-247.
26. Iwasaki M, Maruyama I, Ikezeki N, Abe M, Maeyama T, Nagata E, et al. Endotoxin in severe liver disease. Jpn J Gastroenterol. 77:1980;386-394.
27. Liehr H, English G, Rosenack U. Lactulose: a drug with anti-endotoxin effect. Hepatogastroenterology. 27:1980;356-360.
28. Van Vugt H, van Gool J, Thomas LLM. Galactosamine hepatitis, endotoxemia and lactulose. Hepatology. 3:1983;236-240.
29. Bemelmans MH, Greve JW, Gouma DJ, Buurman WA. Increased concentrations of tumor necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors are prognostic factors for mortality. Gut. 38:1996;447-453.
30. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs. 34:1987;50-97.
31. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Ketner P, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood. 78:1991;1205-1211.
32. Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effects of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukocyts Biol. 40:1986;747-757.
33. Tannenbaum CS, Hamilton TA. Lipopolysaccharide induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol. 142:1989;1274-1280.
34. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 172:1990;391-394.
35. Endres S, Fulle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R, et al. Cyclic nucleotides differentially regulate the synthesis of tumor necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. Immunology. 72:1991;56-60.
36. Noel P, Nelson S, Bokulic R, Bagby GJ, Lippton H, Lipscomb G, et al. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci. 47:1990;1023-1029.
37. Akerman P, Cote P, Yang SQ, Mclain C, Nelson S, Bagby GJ, et al. Antibodies to tumor necrosis factor-α inhibit liver regeneration after partial hepatectomy. Am J Physiol. 263:1992;G579-G585.
38. Satoh M, Yamazaki M. Tumor necrosis factor stimulates DNA synthesis of mouse hepatocytes in primary culture and is suppressed by transforming growth factor β and interleukin 6. J Cell Physiol. 150:1992;134-139.
39. Shimizu Y, Shaw S. Lymphocyte interactions with extracellular matrix. FASEB J. 5:1990;2292-2297.
40. Nathan C, Srimal S, Farber C, Sanchez E, Kabbash L, Asch A, et al. Cytokine-induced respiratory burst of human neutrophils depends on extracellular matrix proteins and CD11/CD18 integrins. J Cell Biol. 109:1989;1341-1349.
41. Tighe D, Moss R, Hynd J, Boghossian S, al-Saady N, Heath MF, et al. Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit Care Med. 18:1990;184-189.
42. Zheng J, Crowley J, Chan JH, et al. Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminescence. Am Rev Respir Dis. 142:1990;1073-1078.
43. Sullivan GW, Carper HT, Mandell GL. Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro. Antimicrob Agents Chemother. 36:1992;408-416.
44. Edwards MJ, Heniford BT, Klar EA, Doak KW, Miller FN. Penyoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J Clin Invest. 90:1992;637-641.
45. Fraissinette AD, Berman B, Duncan MR, Lefevre L. Effect of pentoxifylline on interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF alpha) induction of intercellular adhesion molecule-1 (ICAM-1) expression on human normal keratinocytes and Langerhans cells. Eur J Dermatol. 23:1992;104-114.
46. Hershkoviz R, Cahalon L, Miron S, Alon R, Sapir T, Akiyama S, et al. TNF-α associated with fibronectin enhances phorbol myristate acetate- or antigen-mediated integrin-dependent adhesion of CD4+ T cells via protein tyrosine phosphorylation. J Immunol. 153:1994;554-565.
47. Lebovics E, Casellas A, Dworkin B, Chan S, Rosenthal WS. Pentoxifylline enhances response of chronic hepatitis C to interferon α2b: interim report of a double-blind randomized controlled trial. J Hepatol. 1996;25. (suppl 1): C01/045.